Ilan Ganot, Solid Bio CEO (Solid Bio)

Sol­id Bio’s long, trou­bled slog through the clin­ic yields 'en­cour­ag­ing' ear­ly da­ta and no new safe­ty con­cerns. It's not win­ning over in­vestors yet

Those who have been fol­low­ing the gene ther­a­py space would be fa­mil­iar with Sol­id Bio’s IG­NITE-DMD tri­al. Be­set with safe­ty is­sues, the Phase I/II study was held down by clin­i­cal holds for the bet­ter part of the last three years, while the Duchenne-fo­cused biotech watched big­ger ri­vals dash by to­ward piv­otal work.

There was just one thing that we’ve nev­er seen: da­ta from the study on how pa­tients are do­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.